CGS 24012 (DPMA)

adenosine agonist with both high affinity & selectivity for the adenosine A2 receptor

Also Known As:

DPMA; CGS-24012; DPMPEA; N(6)-(2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl)adenosine; PD 125944; PD-125944

Networked: 18 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        CGS 24012: 18
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Adenosine: 12431
      - CGS 24012: 18
  - Ribonucleosides: 49
    - Adenosine: 12431
      - CGS 24012: 18

Experts

1.	Chang, Candace: 1 article (01/2021)
2.	Duan, Ling: 1 article (01/2021)
3.	Fang, Jing: 1 article (01/2021)
4.	Jacobs, Jonathan P: 1 article (01/2021)
5.	Jing, Bo: 1 article (01/2021)
6.	Khalique, Abdul: 1 article (01/2021)
7.	Ni, Xueqin: 1 article (01/2021)
8.	Niu, Lili: 1 article (01/2021)
9.	Pan, Kangcheng: 1 article (01/2021)
10.	Pu, Yang: 1 article (01/2021)

Related Diseases

1.	Bites and Stings (Sting) 03/01/2023 - "CVVH+DPMA+HP regimen can significantly reduce the APACHE II score of patients with severe wasp sting injury, and the efficacy is superior to CVVH+HP and CVVH+PE regimens, with safety." 03/01/2023 - "From July 2020 to October 2022, patients with wasp sting injury and multiple organ damage admitted to the intensive care units (ICU) of five hospitals were consecutively screened and recruited into the CVVH+DPMA+HP group (intervention group). " 03/01/2023 - "To compare the effect and safety of continuous veno-venous hemofiltration (CVVH)+double plasma molecular absorption (DPMA)+hemoperfusion (HP), CVVH+HP, and CVVH+plasma exchange (PE) in treatment of patient with severe wasp stings injury. "
2.	Body Weight (Weight, Body) 11/01/2016 - "This study reinforces the use of the contraceptive DPMA and the need for guidance related to living a healthy lifestyle for women who attribute the increase of body weight to the use of the method."
3.	Hemorrhage 07/19/2006 - "Although the duration of bleeding and spotting events was the same in each group, women on DPMA were 21% more likely to develop amenorrhoea. " 04/01/1984 - " NET-O EN acceptors were more likely to experience heavy or prolonged bleeding while DPMA acceptors were more likely to report amenorrhea or a decreased flow. "
4.	Ganglion Cysts (Ganglion) 01/01/2011 - "Moreover, DPMA as well as the adenosine uptake blocker nitrobenzyl mercaptopurine riboside (NBMPR) modulate cell survival and CREB phosphorylation in a population of cells in the ganglion cell layer in vivo. "
5.	Tetanus 10/01/1997 - "A slow onset NMDA-independent LTP could be induced by application of a tetanus during perfusion of DPMA with the NMDA blocker AP5 (50 microM). "

Related Drugs and Biologics

1.	Contraceptive Agents (Contraceptives)
2.	Adenosine (Adenocard)
3.	3,7-dimethyl-1-propargylxanthine
4.	Tight Junction Proteins
5.	Adenosine A2 Receptor Agonists
6.	Adenosine A2 Receptors
7.	Adenosine A1 Receptor
8.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9.	Adenosine-5'-(N-ethylcarboxamide) (NECA)
10.	Dextran Sulfate

Related Therapies and Procedures

1.	Hemoperfusion
2.	Continuous Renal Replacement Therapy